Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
JAMA Oncology - United States
doi 10.1001/jamaoncol.2018.2969
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2018
Authors
Publisher
American Medical Association (AMA)